Wolfe Research Upgrades MoonLake to Outperform, Raises Price Target to $24
3/23/2026
Impact: 80
Healthcare
Wolfe Research analyst Andy Chen has upgraded MoonLake (NASDAQ: MLTX) from Underperform to Outperform. The price target for the stock has been raised significantly from $12 to $24.
AI summary, not financial advice
Share: